Cephalon rejects Valeant takeover offer
April 06, 2011 at 11:30 AM EDT
Biotech firm’s board says Valeant’s $73-a-share offer is “inadequate” and “opportunistic,” while the suitor takes its fight direct to Cephalon shareholders.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.